What we are studying
The purpose of this study is to find out what effects (good and bad) BIIB054 has on subjects and their condition (Parkinson's disease). BIIB054 is an investigational drug and has not been approved by the FDA. It is believed to work by attaching to molecules in your brain associated with Parkinson's disease, called alpha-synuclein, and preventing them from causing damage.
BIIB054 will be compared to placebo and will be given by I.V. every 4 weeks.
You will be reimbursed for approved travel expenses related to study visits.